GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial!
Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants
We were having cocktails at a fancy restaurant last night with a hedge fund manager, who manages...
GeoVax Labs (GOVX) JP Morgan 2024 Healthcare Conference Transcript.
ILLUSTRATION 3 |MISSION AND STRATEGY
Our mission: One is to innovate. The other one is to differentiate. The other one is to accelerate and finally...
Revive Therapeutics (RVVTF) $0.02, Explores the Use of Bucillamine for Long COVID.
Bucillamine is one of the most amazing drugs (in our opinion), which was repurposed from its original use as an anti-inflammatory for use with...
Adding GeoVax (GOVX) $3.32 to Reverse Stock Split Watch List.
Okay, Here's Our First Name for the Reverse Stock Split, Watch List. We'll Venture to Have 10 Names Added to Watch List Within 30...
Corbus Pharma (CRBP) Explodes Higher After Reverse Split, up 1,288%!
From a Low of $2.11 Just Shy of a Year Ago, to an Intraday High of $29.30. A Ten Bagger in Less Than a...
Zivo Bioscience (ZIVO) Screams 2,608% Higher AFTER Reverse Split!
Okay, that's it. We are officially enamored with post reverse split trading!
First, there was our client, LQR House (LQR), then Polished (POL) and...
ATCC Announces $87 Million Award for Project NextGen for Vaccines, from Barda.
ATCC, the world’s premier biological materials management and standards organization, today announced a five-year, $87 million award from the Biomedical Advanced Research and Development...
Ardelyx (ARDX), Raymond James up Price Target, Citigroup Joins the Party.
Wall Street Cozy's up to Ardelyx After New Guidance.
On January 8th, Mike Raab, President and Chief Executive Officer stated, "We consistently grew sales of...
Is David Dodd on to his Next Billion Dollar Payday for Shareholders?
Huge News: Gedeptin® Therapy Demonstrated Safety, Stabilization and Shrinkage of Treated Tumors.
GeoVax (GOVX) Completes Patient Enrollment for Head & Neck Cancer Drug, Gedeptin.®
David...
Citius Pharmaceuticals, Inc. (CTXR) Reports Fiscal Full Year 2023 Financial Results and Provides Business...
Mino-Lok® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024
LYMPHIR™ BLA resubmission on track for early 2024
CRANFORD, N.J., Jan. 2, 2024 /PRNewswire/ -- Citius Pharmaceuticals,...















